Video

Introducing a Genomic Era in ET

Genomics are starting to play a crucial role in treatment planning for patients with essential thrombocythemia.

When it comes to planning treatment for patients with essential thrombocythemia (ET) — a type of myeloproliferative neoplasm (MPN) — identifying the presence of the JAK2 genetic mutation and understanding its significance can be very important, according to Laura Michaelis, M.D., associate professor of medicine at the Medical College of Wisconsin.

ET is being ushered into the genomic era as treatment protocols are being changed based on a patient’s mutational status. For example, if a patient does not have a JAK2 mutation, he or she is less likely to experience thrombosis and may not need to undergo cytoreductive therapy to control bleeding, regardless of the age at diagnosis. This is an important shift in the treatment paradigm and may prevent patients from having unneeded treatment.

Related Videos
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Related Content